H5N1 vaccines: how prepared are we for a pandemic? (Q30356899)

20 June 2017

H5N1 vaccines: how prepared are we for a pandemic? (English)

1 reference

20 June 2017

0 references

pandemic preparedness

1 reference

Iain Stephenson

1

1 reference

PubMed ID

16980092

20 June 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

20 June 2017

1 reference

20 June 2017

368

1 reference

20 June 2017

965-966

1 reference

20 June 2017

9540

1 reference

Characterization of the reconstructed 1918 Spanish influenza pandemic virus

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Confronting the avian influenza threat: vaccine development for a potential pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Preparing for pandemic vaccination: an international policy agenda for vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Trials of Influenza A/New Jersey/76 Virus Vaccine in Normal Children: An Overview of Age-Related Antigenicity and Reactogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969340-9

7 January 2021

10.1016/S0140-6736(06)69340-9

Identifiers

DOI

1 reference

20 June 2017

1 reference

PubMed ID

16980092